SCIENCE & TECHNOLOGY
Receptor editing – which was initially described in immunology – is a regulation mechanism of key receptors (e.g. 5HT2cR, AMPAR) involved in brain diseases (such as depression, schizophrenia or neurodegenerative diseases) or in the mechanism of action of pharmacological agents (such as an antidepressant or anti-obesity drugs). Biocortech has developed the only technology enabling a…
Read MoreBOARD OF DIRECTORS
Dinah Weissmann Chairman of the Board, Chief Executive Director Jean François Pujol Director, Chief Scientific Director Jean Paul Leon Director Previously CFO and Executive VP Corporate Strategy of Sanofi. Jean-Paul is an expert of the big pharma environment. As a previous member of Sanofi top management, he was a strong contributor for more 25 years…
Read MoreManagement Team
Dinah Weissmann has served as Biocortech Chief Executive Officer since the founding of the company in 2001. Dr Weissmann is an expert in neurobiology, with 20 years’ experience in R&D; management. Prior to founding Biocortech, Dinah was a Senior Scientist at Roussel Uclaf (now Sanofi-Aventis). Her research background includes an appointment as a Research Director at…
Read MoreBusiness strategy
Diagnostics Biocortech is completing clinical proof of concept of its in vitro diagnostics tests for disease management of brain disorders and is interested in collaborating on their regulatory development, industrialization, marketing and commercialization, with industry partner(s) having a franchise in in vitro diagnostic market. Biocortech contemplates possibilities to develop and commercialize diagnostic tests for niche…
Read MoreHome
Biocortech is focusing on developing diagnostic application of receptor editing, an emerging field of rapidly growing interest that the company pioneered for the last years. Biocortech is now addressing the emerging market of biological testing of neuropsychiatric diseases and aiming at being an early entrant in the market of biological testing of depression, with a proprietary…
Read More